Immuno-oncology is a unique approach to cancer treatment based on an innovative platform that harnesses the patient's own T cells to attack the cancer. The T-cells can be derived from resected tumors (called TIL tumor-infiltrating lymphocytes) or genetically engineered T-cells recognizing tumor antigens, T-cell receptors (TCR) or chimeric antigen receptors (CAR).

Encouraging clinical results have accelerated the progress of these therapies as they have emerged as one of the most effective ways of leveraging the potential of the immune system. For example, CAR T-cell therapy resulted in up to 90% positive response in severely ill leukemia patients.

The T-cell immunotherapy market targets both hematological cancers and solid tumors. It is predicted that the T-cell therapy market will be expanding at a growth rate of over 100% per year. Some of the forecasts have estimated this market to reach USD 30 billion by 2030.

Major progress in this field has resulted from close collaboration between research institutes and industry. The T-cell immunotherapy market is seeking partnerships with technology providers, especially those with capabilities in research and development, manufacturing and viral and non-viral gene transfer platforms.

Orgenesis has partnered with some of the leading players in the immuno-oncology field and we believe that if these treatments are successful, it could result in rapid and significant growth for our cell manufacturing operations.